Stéphane Bancel

Bancel, who grew up in France and holds an M.B.A. from Harvard Business School as well as two master’s degrees in engineering from École Centrale Paris and the University of Minnesota, joined Moderna Therapeutics in 2011. Before that, he served as CEO of French diagnostics company BioMérieux, founded by fellow billionaire Alain Mérieux; Bancel’s former employer is also involved in the COVID-19 fight, with its subsidiary recently gaining FDA approval for a new 45-minute testing kit. Forbes estimates Bancel’s net worth at just over $1 billion, based on his roughly 9% stake in the publicly traded company. Moderna’s stock is up 44% since it went public in December 2018. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. He currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston.